J01 Effects of IONIS-HTTRX (RG6042) in patients with early huntington’s disease, results of the first htt-lowering drug trial
Year: 2018
Type: conference-abstract
Authors: Sarah J Tabrizi, Blair Leavitt, Bernhard Landwehrmeyer, Edward Wild, Carsten Saft, Roger Barker, David Craufurd, Hugh Rickards, Anne Rosser, Josef Priller, Holly Kordasiewicz, Christian Czech, Eric Swayze, Daniel A Norris, Tiffany Baumann, Irene Gerlach, Scott Schobel, Anne Smith, Roger Lane, C Frank Bennett, on behalf of the HTT Rx CS1 study teams
Institutions: UCL Queen Square Institute of Neurology, University College London, University of British Columbia, Universität Ulm, St. Josef-Hospital, Ruhr University Bochum, University of Cambridge, Addenbrooke's Hospital, Manchester Academic Health Science Centre, University of Manchester, University of Birmingham, Cardiff University, Charité – Universitätsmedizin Berlin, Ionis Pharmaceuticals (United States), F. Hoffmann-La Roche AG
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: closed
Funder: Medical Research Council
Award: G1660387998
OpenAlex ID: W2891263300